Applying Antithrombotic Therapies to Improve Outcomes in Patients with Atrial Fibrillation
Approximately 15-25%, or 75,000 ischemic strokes are attributed to atrial fibrillation annually within the United States. Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia and affects more than 2.66 million Americans. Moreover, atrial fibrillation is associated with a 1.5 - 1.9 fold higher risk of death, due to its strong correlation with thromboembolic events. Because of the attributed increased morbidity and mortality, challenges that concern identification of patients at risk for thromboembolic events from atrial fibrillation must be addressed. These challenges include compliance to performance measures, adherence to guidelines, adequate prevention and early control of comorbidities that affect the progression of atrial fibrillation and associated risks, early initiation of treatment and successful evaluation of associated risks of bleeding, primary or recurrent stroke, and patient awareness and compliance.
This multimedia educational webcast will discuss the state of affairs with respect to antithrombotic therapies and new anticoagulants. The webcast will also review factors influencing physician use of anticoagulation in atrial fibrillation. Clinical decision making and lessons learned from the expert faculty is also included.
Cardiologists, internists, and physicians who care for patients with atrial fibrillation.
Upon completion of this activity, participants will be able to:
- Describe and apply the AHA/ACC/ESC guidelines for the management of atrial fibrillation with anticoagulant therapy, utilizing appropriate risk-stratification, updated data, and standards of care.
- Translate the results of evolving clinical trials to clinical practice with respect to the management of anticoagulants for patients with atrial fibrillation including that on safety, bleeding risk, and efficacy.
- Implement communication tools and strategies that activate the patient thereby increasing compliance to optimize outcomes.
|Chris Cannon, MD, FACC |
Professor, Dept. of Medicine
Harvard Medical School
Brigham and Women's Hospital
|Michael D. Ezekowitz, MBChB, DPhil, FACC|
Professor, Dept. of Medicine
Jefferson Medical College, Philadelphia, PA
Director, AF Research and Education CRF
New York, NY
|Christopher Granger, MD, FACC|
Professor, Dept. of Medicine
Director, Cardiac Care Unit
Duke University Medical Center
It is the policy of the Elsevier Office of Continuing Medical Education (EOCME) that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With|
Chris Cannon, MD, FACC
Consultant/Advisor: Alnylam Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Pfizer Inc., and CSL Behring
Research Grant: Accumetrics, AstraZeneca, Essentialis, Inc., GlaxoSmithKline, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis, Takeda Pharmaceutical Company LimitedStock Ownership: Automedics Medical Systems, Inc.
Michael D. Ezekowitz, MBChB, DPhil, FACC
Consultant/Advisor: Aegerion Pharmaceuticals, Inc., Bayer Healthcare, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Coherex Medical, Inc., Daiichi Sankyo, Inc., Gilead Sciences, Inc., Janssen Scientific Affairs, LLC, Johnson & Johnson, Inc., Medtronics, Inc., Merck & Co., Inc., Pfizer Inc., Portola Pharmaceuticals, Inc, Pozen, Inc., sanofi-aventisGrant/Research Support: Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc., Portola Pharmaceuticals, Inc.
Christopher Granger, MD, FACC
Consultant/Advisor: AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Hoffman La-Roche, Ltd., Pfizer Inc., sanofi-aventis, Takeda Pharmaceutical Company Limited, The Medicines CompanyGrant/Research Support: Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Medtronic Foundation, Merck & Co., Inc., Pfizer Inc., sanofi-aventis, Takeda Pharmaceutical Company Limited, The Medicines Company
Planners, Managers, Reviewers: Timothy Hayes, MD, PhD, Margaret Taylor, Gena Dolson, MS, Esther Polgar, Sandy Breslow, Jill McNair, and Karen Overstreet, EdD, RPh, FACEHP, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
This enduring material has been peer-reviewed by the American Journal of Cardiology.
The EOCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Boehringer Ingelheim Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- AMA PRA Category 1 Credit(s)™: 1.00
- Non-physician: 1.00
- Course opens: April 01, 2013
- Course expires: March 31, 2014